共 1125 条
[1]
Davies MJ(2018)Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetologia 61 2461-2498
[2]
D’Alessio DA(2018)Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2018 executive summary Endocr Pract 24 91-120
[3]
Fradkin J(2015)Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes N Engl J Med 373 2117-2128
[4]
Garber AJ(2017)Canagliflozin and cardiovascular and renal events in type 2 diabetes N Engl J Med 377 644-657
[5]
Abrahamson MJ(2019)Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes New England Journal of Medicine 380 347-357
[6]
Barzilay JI(2015)Lixisenatide in patients with type 2 diabetes and acute coronary syndrome N Engl J Med 373 2247-2257
[7]
Blonde L(2016)Liraglutide and cardiovascular outcomes in type 2 diabetes N Engl J Med 375 311-322
[8]
Bloomgarden ZT(2016)Semaglutide and cardiovascular outcomes in patients with type 2 diabetes N Engl J Med 375 1834-1844
[9]
Bush MA(2017)Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes N Engl J Med 377 1228-1239
[10]
Dagogo-Jack S(2018)Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial Lancet (London, England) 392 1519-1529